Atomwise, Inc.
http://www.atomwise.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Atomwise, Inc.
ADCs, Oncology Move To Fore In Korean Biopharma Alliances
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.
Asia Deal Watch: Bone Therapeutics Licenses Bone Cell Therapy Tech To Two Asian Firms
Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.
Finance Watch: 2020 Cell And Gene Therapy Funding Already Bests 2019
Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.
Deal Watch: Lilly, AbCellera Partner To Attempt Rapid COVID-19 Antibody Development
Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.
Company Information
- Industry
- Digital Health
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools